Q1 Earnings Forecast for ELDN Issued By Leerink Partnrs

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Eledon Pharmaceuticals in a report released on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.29) EPS.

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Trading Down 2.9 %

Shares of Eledon Pharmaceuticals stock opened at $3.37 on Tuesday. Eledon Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.54. The company has a market cap of $201.80 million, a P/E ratio of -1.68 and a beta of 0.80. The stock has a 50-day moving average price of $4.14 and a 200 day moving average price of $3.88.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same period last year, the business earned ($1.00) earnings per share.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Inspire Investing LLC acquired a new stake in Eledon Pharmaceuticals during the fourth quarter valued at $802,000. Geode Capital Management LLC raised its stake in shares of Eledon Pharmaceuticals by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after purchasing an additional 33,569 shares in the last quarter. Kera Capital Partners Inc. acquired a new stake in shares of Eledon Pharmaceuticals during the 4th quarter valued at about $106,000. Boothbay Fund Management LLC bought a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $1,409,000. Finally, First Light Asset Management LLC acquired a new position in Eledon Pharmaceuticals in the fourth quarter worth approximately $9,595,000. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).